HSA alerts public of low-levels of contamination in ranitidine
The US Food and Drug Administration (FDA) has issued a statement regarding the safety of the drug ranitidine (Zantac®) after the detection of low-levels of contamination.
The FDA and several health regulatory bodies including the Health Canada and the European Medicines Agency are conducting an evaluation on this matter.
The Cayman Islands Health Services Authority (HSA) is aware of the issue and is closely monitoring the evaluation. Once the aforementioned agencies release more information, the HSA will provide an update. In the meantime, the organization is recommending that patients continue taking their ranitidine as prescribed.
24 Sep, 2019
25 Feb, 2020
28 Jun, 2019
18 Nov, 2019
Comments (0)
We appreciate your feedback. You can comment here with your pseudonym or real name. You can leave a comment with or without entering an email address. All comments will be reviewed before they are published.